Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

5802 - Survival of HER2-positive advanced breast cancer patients treated with lapatinib plus capecitabine – a national population-based study: long-term analysis.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Targeted Therapy;  Breast Cancer

Presenters

Beata Jagielska

Citation

Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272

Authors

B. Jagielska1, P. Tokajuk2, T. Pieńkowski3, A. Czubek1, M.J. Krzakowski4, M.Z. Wojtukiewicz2

Author affiliations

  • 1 Department Of Oncology Diagnostics, Cardioncology And Palliative Medicine, Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), 02-781 - Warsaw/PL
  • 2 Clinical Oncology, Comprehensive Cancer Center Bialostockie Centrum Onkologii, 15-027 - Bialystok/PL
  • 3 Onkologia Kliniczna, Radomskie Centrum Onkologii, 26-600 - Radom/PL
  • 4 Department Of Lung & Thoracic Tumours, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, 02-781 - Warsaw/PL
More

Resources

Abstract 5802

Background

In Poland, governmental policy was to offer a uniform, national therapeutic programme for the treatment of HER2-positive advanced breast cancer (ABC) patients (pts). Accordingly, the Polish Breast Cancer Treatment Programme was introduced. Herein, we present first results of this effort from the cohort of previously-treated patients who underwent anti-HER2 palliative therapy with lapatinib plus capecitabine.

Methods

The aim of the study was to assess the population-based value of lapatinib plus capecitabine therapy of HER2-positive ABC patients treated within the Polish Breast Cancer Treatment Programme during the years 2008-2015. Patients have been prospectively enrolled into aforementioned programme and treated according to the specified protocol. We used Kaplan-Meier method to evaluate progression-free survival (PFS), time to tumor progression (TTP) and overall survival (OS). The effects of clinical and demographic factors on PFS and OS were assessed using Cox’s proportional hazards regression model.

Results

A total of 1018 HER2-positive ABC women were enrolled into the Polish Breast Cancer Treatment Programme on a national level. Patients who progressed after regimens that included, but were not limited to, anthracyclines, taxanes, and trastuzumab were eligible to this study. Median age of the patients was 56.6 years (range, 22.8 to 86.1). Previous adjuvant therapy: 35.7% pts; ER(+)/PgR(+): 47.5% pts; number of metastatic sites ≥2: 45.9% pts. The median PFS was 6.4 months and median TTP was 6.7 months. The median OS was 11.76 months (range, 0.36-70.32). The overall response rate was 13%. Cox regression model data will be presented.

Conclusions

To our knowledge this study represents one of the first reports assessing the population-based value of a lapatinib/capecitabine treatment in clinical practice. Our data essentially corroborated findings obtained from randomized clinical trials. It seems that treatment with lapatinib and capecitabine is associated with a meaningful clinical effectiveness and therefore warrants consideration in the treatment algorithm of HER2-positive ABC patients.

Clinical trial identification

Legal entity responsible for the study

Beata Jagielska.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.